Please login to the form below

Not currently logged in

aTyr appoints rare disease expert as president

Frederic Chereau has senior experience at Shire and Genzyme

US-based firm aTyr Pharma has appointed Frederic Chereau as president and chief operating officer to support the advance of its portfolio of medicines for rare diseases.

Chereau has significant experience in the field, working at rare disease specialist Genzyme from 1999 to 2008, eventually becoming president and general manager of the company's cardiovascular business.

He was later president and CEO of Pervasis Therapeutics, which was acquired by Shire in 2012.

Dr John Mendlein, CEO and executive chairman of aTyr Pharma, said that Chereau's appointment will guide the company's “global outreach and strategic partnerships”.

7th February 2014

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...